Trial Radar KI | ||
|---|---|---|
enums.trial_summary.trial_summary_welcome | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans (DGA4ME)
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT04293224 (DGA4ME) ist eine interventionsstudie zur Untersuchung von Fettleibigkeit, Körpergewicht und hat den Status offene rekrutierung. Die Studie startete am 1. August 2022 und soll 70 Teilnehmer aufnehmen. Durchgeführt von USDA, Western Human Nutrition Research Center ist der Abschluss für 30. September 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 20. November 2025 aktualisiert.
Kurzbeschreibung
This study, at the Western Human Nutrition Research Center (WHNRC), will focus on whether or not achieving and maintaining a healthy body weight is the most important health promoting recommendation of the Dietary Guidelines for Americans (DGA).The investigators hypothesize that improvement in cardiometabolic risk factors resulting from eating a DGA style diet will be greater in people whose energy intake is restricted to result in weight loss compared to those who maintain their weight. The investigators further propose that during a state of energy restriction, a higher nutrient quality diet such as the DGA style diet pattern, will result in greater improvement in cardiometabolic risk factors compared to a typical American diet (TAD) pattern that tends to be lower nutrient quality (more energy-dense and less nutrient-rich.)
Ausführliche Beschreibung
This will be a 28-week study including pre-diet testing (week 1), an 8-week controlled feeding period, post-diet testing (week 10), a follow-up period of dietary education and observation, and end of study testing (week 28). During the 8 week feeding, participants will be randomly assigned one of the following diets:
- DGA Mediterranean diet pattern at sufficient energy level to maintain body weight (energy balance)
- DGA Mediterranean diet pattern at a moderately reduced energy level (negative energy balance)
- TAD diet pattern at a moderately reduced energy level (negative energy balance)
In the follow-up phase, the investigators will evaluate how multiple factors may influence body weight management, including previous dietary exposure, as well as the role of cognitive function, executive function, genetics, habitual diet, physical activity, eating behavior, stress and stress responsivity, metabolic flexibility and gut microbiome.
Offizieller Titel
Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans
Erkrankungen
FettleibigkeitKörpergewichtPublikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:Weitere Studien-IDs
- DGA4ME
- FL111
NCT-Nummer
Studienbeginn (tatsächlich)
2022-08-01
Zuletzt aktualisiert
2025-11-20
Studienende (vorauss.)
2026-09-30
Geplante Rekrutierung
70
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Offene Rekrutierung
Stichwörter
Dietary Guidelines for Americans
Physical Activity for Americans
Mediterranean Diet
Controlled Feeding
Women
PreDiabetes
Metabolic Syndrome
Cognitive Function
Stress, Physiological
Executive Function
Cardiovascular Diseases
Cardiovascular Risk Factor
Eating Behavior
Glucose Intolerance
Metabolomic Profiling
Metabolic flexibility
Gut Microbiome
Genome Testing
Prehypertension
Insulin Resistance
Insulin Sensitivity
Hypertriglyceridemic
Waist to Hip Ratio
Allostatic Load
Physiology
Physical Activity for Americans
Mediterranean Diet
Controlled Feeding
Women
PreDiabetes
Metabolic Syndrome
Cognitive Function
Stress, Physiological
Executive Function
Cardiovascular Diseases
Cardiovascular Risk Factor
Eating Behavior
Glucose Intolerance
Metabolomic Profiling
Metabolic flexibility
Gut Microbiome
Genome Testing
Prehypertension
Insulin Resistance
Insulin Sensitivity
Hypertriglyceridemic
Waist to Hip Ratio
Allostatic Load
Physiology
Primäres Ziel
Grundlagenforschung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellDGA Mediterranean diet pattern, energy balance Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations. | DGA Mediterranean Diet Pattern, Energy Balance Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations. |
ExperimentellDGA Mediterranean diet pattern, negative energy balance Negative energy balance (\~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations. | DGA Mediterranean Diet Pattern, Negative Energy Balance Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations |
ExperimentellTAD diet pattern Typical American Diet (TAD) with negative energy balance (\~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA). | TAD Diet Pattern, Negative Energy Balance Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in body weight | Body weight will be measured to the nearest 0.1 kg using a calibrated electronic scale. | Measured weekly for weeks 1 through 10, and weeks 13, 17, 21, 24 and 28 |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Height | Height will be measured to the nearest 0.1 cm using a wall-mounted stadiometer. | Week 1 |
Change in body mass index | Body weight and height will be used to calculate Body Mass Index (BMI) as kg/m2. | Measured weekly for weeks 1 through 10, and weeks 13, 17, 21, 24 and 28 |
Change in body water (via InBody) | Measured using bioelectrical impedance analysis (BIA) with an InBody 770® expressed as kg. | Week 1, 10, 28 |
Change in body fat (via DEXA scan) | Fat mass (grams) will be measured using dual energy x-ray absorptiometry (DEXA). | Week 1, 10, 28 |
Change in waist circumference | Waist circumference is measured with an anthropometric tape. Measurements will be performed in duplicate and averages recorded to the nearest 0.1 cm. | Week 1, 10, 28 |
Change in hip circumference | Hip circumference is measured with an anthropometric tape. Measurements will be performed in duplicate and averages recorded to the nearest 0.1 cm. | Week 1, 10, 28 |
Change in waist to hip ratio | Waist and hip circumference will be expressed as a ratio. | Week 1, 10, 28 |
Change in resting systolic blood pressure | Blood pressure will obtained via automated instrument and blood pressure cuff. At least two measurements will be made, expressed in mmHg, and the average value will be recorded. | Week 1, 10, 28 |
Change in resting diastolic blood pressure | Blood pressure will obtained via automated instrument and blood pressure cuff. At least two measurements will be made, expressed in mmHg, and the average value will be recorded. | Week 1, 10, 28 |
Change in resting heart rate | Resting heart rate (pulse) will obtained via automated instrument in beats per minute. | Week 1, 10, 28 |
Genetic Risk of Obesity | Genomic DNA will be collected from white blood cells. A polygenic risk score (PRS) indexing genetic predisposition to obesity using known obesity single nucleotide polymorphisms (SNPs). | Week 1 |
Change in vascular health | Peripheral Arterial Tone (PAT) technology will be used to measure vascular health. The EndoPAT test is a non-invasive measurement of the overall health of the endothelium. | Week 1, 5, 10 |
Change in liver fat | Liver fat assessed from the Controlled Attenuation Parameter (CAP) computed from the liver stiffness measurement using the Fibroscan® | Week 1 and 10 |
Change in liver stiffness | Liver stiffness assessed from the shear wave speed with pulse echo ultrasound using the Fibroscan® | Week 1 and 10 |
Change in blood metabolite profiles | Analysis of metabolites, the small molecule substrates, intermediates and products of metabolism analyzed by mass spectrometry (MS). Includes branched chain amino acids, 2 hydroxybutyric acid, acylcarnitines, saturated, monounsaturated and polyunsaturated non-esterified fatty acids, triglyceride species, phospholipid species, bile acids and steroid hormones. | Week 1 and 10 |
Change in fasting blood glucose | This outcome will evaluate blood sugars levels in the fasted state. | Week 1, 10, 28 |
Change in hemoglobin A1C | This outcome will evaluate glycated hemoglobin as a reflection of the plasma glucose level during the past two to three months. | Week 1, 10, 28 |
Change in urinary sodium | Urinary sodium will be measured as indicators of dietary compliance during the feeding intervention of the study. All urine passed for a 24 hour period will be collected. | Week 1, 5, 7 and 10 |
Change in urinary potassium | Urinary potassium will be measured as indicators of dietary compliance during the feeding intervention of the study. All urine passed for a 24 hour period will be collected. | Week 1, 5, 7 and 10 |
Change in urinary nitrogen | Urinary nitrogen will be measured as indicators of dietary compliance during the feeding intervention of the study. All urine passed for a 24 hour period will be collected. | Week 1, 5, 7 and 10 |
Change in red blood cell fatty acids | Red blood cell fatty acids will be analyzed by mass spectrometry (MS). | Week 1, 10, 28 |
Change in C-reactive protein | C-Reactive Protein will be measured as a non-specific marker for inflammation. | Week 1, 10, 28 |
Change in carotenoid levels | Serum carotenoids, including vitamin A, alpha-carotene, and beta-carotene will be used to evaluate nutrient status and dietary intake of vegetables prior to feeding intervention and post feeding intervention. | Week 1 and 10 |
Change in total cholesterol | Total cholesterol will be collected to evaluate cardiac risk expressed as milligrams per deciliter (mg/dL). | Week 1 and 10 |
Change in high density lipoprotein (HDL) cholesterol | HDL cholesterol will be collected to evaluate cardiac risk expressed as milligrams per deciliter (mg/dL). | Week 1 and 10 |
Change in low density lipoprotein (LDL) cholesterol | LDL cholesterol will be collected to evaluate cardiac risk expressed as milligrams per deciliter (mg/dL). | Week 1 and 10 |
Change in triglycerides in response to a meal | Triglycerides will be measured in blood (mg/dL). | Baseline and 1, 2, 3, and 6 hours after a challenge meal |
Change in ghrelin in response to a meal | Ghrelin will be evaluated as an indicator of hunger signaling. | Baseline and 1, 2, 3, and 6 hours after a challenge meal |
Change in leptin in response to a meal | Leptin will be evaluated as an indicator of satiety signaling. | Baseline and 1, 2, 3, and 6 hours after a challenge meal |
Change in insulin in response to a meal | Insulin measured in blood using an antibody based assay. Will also be expressed as the quantitative insulin sensitivity check index (QUICKI). | Baseline and 1, 2, 3, and 6 hours after a challenge meal |
Change in Matsuda Index | Matsuda index will be calculated from plasma glucose and insulin. | Baseline and 1, 2 hours after a challenge meal |
Change in resting metabolic rate | Respiratory gas exchange measurements (oxygen consumption-VO2 and carbon dioxide production-VCO2) will be made to determine metabolic rate using a metabolic cart system. | Week 1 and 10 |
Change in post-prandial metabolic rate | Post-prandial metabolic rate measured using indirect calorimetry. | 1, 2, 3 and 6 hours after a meal |
Change in metabolic flexibility | The formula is designed to deliver approximately 800 kcals total with 60% kcals from fat (approximately 55 g of fat), 25% kcals from carbohydrates, and 15% of kcals from protein. | Week 1 and 10 |
Change in predicted VO2 max | Cardiorespiratory endurance will be evaluated by measuring heart rate (HR) and oxygen consumption (VO2) during a walking graded exercise test on a treadmill. | Week 1, 10, 28 |
Change in interstitial glucose levels | A continuous glucose monitor (CGM) will be used to continuously assess interstitial glucose levels. The Abbott Freestyle Libre Pro Sensor is inserted under the skin on the back of the arm. The sensor will measure the interstitial glucose level every fifteen minutes. Participants will wear the monitors for fourteen days. | Week 1 and 10 |
Change in executive function | Assessed using Cambridge Gambling Task (CGT), from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in response speed | Assessed using Motor Screening Task (MOT), from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in verbal memory | Assessed using Verbal Recognition Memory (VRM) task from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in psycho-motor speed | Assessed using Reaction Time (RTI) task from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in spatial memory | Assessed using Spatial Working Memory (SWM) task from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in multitasking | Assessed using Multitasking Test (MTT) from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in social cognition | Assessed using Emotional Recognition (ERT) task from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in attentive function | Assessed using Stop Signal Task (STT) from Cambridge Neuropsychological Test Automated Battery (CANTAB). | Week 1 and 10 |
Change in allostatic load | Allostatic load (AL) is an aggregate value derived from several parameters that assess physiologic adaptive response to neural or neuroendocrine stressors. The following measures are used to determine the AL score: Urinary cortisol and catecholamine levels, resting blood pressure, waist to hip ratio, blood levels of high sensitivity C-Reactive Protein, cholesterol, dehydroepiandrosterone sulfate and hemoglobin A1c, and urinary levels of epinephrine and norepinephrine. | Week 1, 10, 28 |
Change in continuous systolic blood pressure | Blood pressure measured using a Continuous Non-invasive Arterial Pressure (CNAP®) device in mmHg. | Week 1 and 10 |
Change in continuous diastolic blood pressure | Blood pressure measured using a Continuous Non-invasive Arterial Pressure (CNAP®) device in mmHg. | Week 1 and 10 |
Change in mean arterial blood pressure | Blood pressure measured using a Continuous Non-invasive Arterial Pressure (CNAP®) device in mmHg . | Week 1 and 10 |
Change in mood | Mood assessed using the Profile of Mood States (POMS). Total Mood Disturbance (TMD) score is found from the difference between "negative" subscales - "positive" subscales. Individual scores on the POMS range from -32 to 200 with higher scores indicating higher mood disturbance. | Week 1 and 10 |
Change in perceived stress | Perceived stress measured using the Perceived stress scale (PSS). Scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Responses for individual questions are summed to a total score. | Week 1, 6, 10, 19 and 28 |
Change in self-efficacy | This 20 item questionnaire is a measurement of the capacity to execute behaviors necessary to change their weight and begin to implement exercise in their lives regularly. | Week 10, 19 and 28 |
Change in diet satisfaction | This 28 item questionnaire acts as a valid instrument for assessing diet satisfaction in the context of weight-management. This measurement assesses diet satisfaction both within and outside the context of weight-loss treatment, as well as to assesses change in satisfaction as a result of treatment. | Week 1, 19 and 28 |
Change in appetite | A computer tablet with stylus will be used to assess hunger and appetite, defined as perceived hunger, fullness, desire to eat, prospective consumption and other measures of food craving and perceived hypoglycemia. Questions will be presented one-by-one on the screen and participants will be asked to express their response using visual analog scales (VAS). This measurement will be evaluated during the meal challenge assessment. | Week 1 and 10 |
Three factor eating questionnaire | This 18 item questionnaire is used to examine three dimensions of human eating behavior including cognitive restraint, disinhibition or uncontrolled eating and hunger. | Week 1 and 10 |
Barriers to physical activity | Participants will be asked to complete the Barriers to Being Active questionnaire. | Week 1 |
Usual physical activity | An accelerometer (Actical) will be continuously worn by participants during waking hours (excluding bathing and swimming) for a period of 7 days.The measure of usual physical activity is used to estimate total energy expenditure and energy requirements. | Week 1 |
Diet acceptability | This measurement is an evaluation of palatability, ease of preparation, satisfaction, and perceived benefits and adverse effects related to a prescribed controlled feeding diet. | Week 10 |
Yale Food Addiction Scale | Measures markers of substance dependence with the consumption of high fat/high sugar foods. This is a 25-item self-report measure that includes mixed response categories (dichotomous and Likert-type format). | Week 1 |
Changes in dietary intake | Three non-consecutive twenty-four hour dietary recalls will be collected when subjects are self-selecting their 'usual' diets. A three day average nutrient intake will be expressed. | Week 1, 19, and 28 |
Change in stress reactivity | Acute stress reactivity will be assessed by measuring salivary cortisol concentrations in response to a challenging task. | Week 1 and 10 |
Change in heart rate variability | Autonomic physiological functioning will be assessed using the MindWare Cardio/Galvanic Skin Response (GSR) system, a device that connects to the subject's torso with eight disposable electrodes and a heart rate monitor. Emotional arousal via skin conductance, a form of electrodermal activity (EDA) is also measured. | Week 1 and 10 |
Change in Food Choice | Food choice computer-based tests from Leeds, United Kingdom, will be used to estimate explicit liking and implicit wanting for several different categories of foods. | Week 1 and 10 |
Change in oxygen consumption rate (OCR) | Measured in peripheral blood mononuclear cells by use of Seahorse XF Analyzer, a tool for measuring glycolysis and oxidative phosphorylation (through oxygen consumption) simultaneously in the same cells. | Week 1 and 10 |
Change in extracellular acidification rate (ECAR) | Measured in peripheral blood mononuclear cells by use of Seahorse XF Analyzer, a tool for measuring glycolysis and oxidative phosphorylation (through oxygen consumption) simultaneously in the same cells. | Week 1 and 10 |
Change in fecal microbiome | Assays will be performed on fecal samples to determine DNA representing the colonic microbiota. | Week 1, 10 an 28 |
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene
Mindestalter
35 Years
Zugelassene Geschlechter
Weiblich
Akzeptiert gesunde Freiwillige
Ja
- Body Mass Index (BMI) 23-39.9 kg/m2 or 32-50% body fat percentage
- Willingness to have blood drawn
- The criteria listed above and at least one of the following: Fasting glucose ≥100 mg/dL but <126 mg/dL or Fasting triglyceride ≥125 mg/dL or HDL-cholesterol ≤50 mg/dL or Blood Pressure (BP): Systolic BP ≥130 mmHg or Diastolic BP ≥85 mmHg or Hemoglobin A1C ≥ 5.7 and <6.5%
- Active participation in another research study
- Tested positive for COVID-19 within the past 10 days
- Been in close contact with a COVID-19 positive person within the past 14 days
- Blood Pressure (BP): Systolic BP ≥140 mmHg or Diastolic BP ≥90 mmHg
- LDL cholesterol ≥190 mg/dL
- Triglycerides ≥500 mg/dL
- Current use of smoking or chewing tobacco, e-cigarettes, cigars, vaping, cannabis or other use of nicotine containing products (within the past 6 months)
- Current use of dietary supplements and/or unwillingness to cease intake of dietary supplements
- Vegan or vegetarian lifestyle or any other dietary restrictions that would interfere with consuming the intervention foods and beverages (including dietary intolerances, allergies and sensitivities)
- Unwillingness to consume intervention foods and beverages
- Engage in more than moderate drinking (> 1 drink serving per day) or binge drinking (4 drinks within two hours).
- Unwillingness to cease alcohol intake as required for specific duration of the study
- Excessive intake of caffeine containing products (excessive defined as ≥ 400 mg/day)
- Unwillingness to refrain from caffeine intake on lab visit days.
- Intentional weight change of ≥5% of body weight within 6 months of entry into the study
- Diagnosis of disordered eating or eating disorder
- Recent diagnosis of any of the following or measurement on screening lab tests: Anemia (hemoglobin <11.7 g/dL) or abnormal liver or thyroid function (defined as liver enzymes that are >200% of upper limit (ALT upper limit is 43 U/L or Aspartate transaminase (AST) upper limit is 54 U/L) and thyroid function tests: Thyroxine (T4, free) <0.56 or >1.64 ng/dL; Thyroid-stimulating hormone (TSH) <0.35 or >5.6 μIU/mL).
- History of any of the following: Gastric bypass surgery, inflammatory bowel disease (IBD) or other GI conditions that would interfere with consuming the intervention foods, active cancer in the past three years excluding squamous or basal cell carcinomas of the skin that have been handled medically by local excision and other serious medical conditions
- Recent dental work or have conditions of the oral cavity that would interfere with consuming the intervention foods and beverages
- Taking any medication in the class of antipsychotics
- Long term use of antibiotics
- Taking any over the counter or prescribed medication for any of the following: Elevated lipids, elevated glucose, high blood pressure, weight loss or conditions that require corticosteroids (e.g. asthma, arthritis or eczema).
- Are pregnant, planning to become pregnant within the duration of the study or breastfeeding.
USDA, Western Human Nutrition Research CenterZentrale Studienkontakte
Kontakt: Beverly Miller, BS, RDN, 530-754-2541, [email protected]
Kontakt: Ellen Bonnel, PhD, 530-752-4184, [email protected]
1 Studienstandorte in 1 Ländern
California
UC Davis, Western Human Nutrition Research Center, Davis, California, 95616, United States
Offene Rekrutierung